EP4153176A4 - Verfahren zur behandlung von krebs - Google Patents

Verfahren zur behandlung von krebs Download PDF

Info

Publication number
EP4153176A4
EP4153176A4 EP20936213.6A EP20936213A EP4153176A4 EP 4153176 A4 EP4153176 A4 EP 4153176A4 EP 20936213 A EP20936213 A EP 20936213A EP 4153176 A4 EP4153176 A4 EP 4153176A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating cancers
cancers
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20936213.6A
Other languages
English (en)
French (fr)
Other versions
EP4153176A1 (de
Inventor
Richard C. CENTORE
Lan Xu
David LAHR
Ammar ADAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foghorn Therapeutics Inc
Original Assignee
Foghorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foghorn Therapeutics Inc filed Critical Foghorn Therapeutics Inc
Publication of EP4153176A1 publication Critical patent/EP4153176A1/de
Publication of EP4153176A4 publication Critical patent/EP4153176A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP20936213.6A 2020-05-20 2020-05-20 Verfahren zur behandlung von krebs Pending EP4153176A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/033829 WO2021236080A1 (en) 2020-05-20 2020-05-20 Methods of treating cancers

Publications (2)

Publication Number Publication Date
EP4153176A1 EP4153176A1 (de) 2023-03-29
EP4153176A4 true EP4153176A4 (de) 2024-05-29

Family

ID=78707458

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20936213.6A Pending EP4153176A4 (de) 2020-05-20 2020-05-20 Verfahren zur behandlung von krebs

Country Status (4)

Country Link
EP (1) EP4153176A4 (de)
JP (1) JP2023535124A (de)
CN (1) CN115867314A (de)
WO (1) WO2021236080A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023204747A1 (en) * 2022-01-07 2024-06-27 Dana-Farber Cancer Institute, Inc. Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4)
WO2023196560A1 (en) * 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196565A1 (en) * 2022-04-08 2023-10-12 Foghorn Therapeutics, Inc. Methods of treating cancer
WO2024086577A1 (en) * 2022-10-17 2024-04-25 Foghorn Therapeutics Inc. Methods of reducing or preventing metastases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152437A1 (en) * 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160100A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160180A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155320A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155316A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114262690A (zh) * 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
WO2014150751A2 (en) * 2013-03-15 2014-09-25 Novartis Ag Biomarkers associated with brm inhibition
EP3020828A4 (de) * 2013-07-12 2017-01-25 National Cancer Center Research Institute Verfahren zur vorhersage der reaktion auf die behandlung von krebs
US9636323B2 (en) * 2014-10-27 2017-05-02 Baylor College Of Medicine Method of treating cancer that overexpresses TopBP1
US20200069669A1 (en) * 2017-02-28 2020-03-05 Epizyme, Inc. Inhibition of smarca2 for treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152437A1 (en) * 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160100A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160180A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155320A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155316A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MILL CHRISTOPHER P ET AL: "RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 134, no. 1, 4 July 2019 (2019-07-04), pages 59 - 73, XP086699061, ISSN: 0006-4971, [retrieved on 20201106], DOI: 10.1182/BLOOD.2018893982 *
See also references of WO2021236080A1 *

Also Published As

Publication number Publication date
WO2021236080A1 (en) 2021-11-25
CN115867314A (zh) 2023-03-28
JP2023535124A (ja) 2023-08-16
EP4153176A1 (de) 2023-03-29

Similar Documents

Publication Publication Date Title
EP4153176A4 (de) Verfahren zur behandlung von krebs
EP3883580A4 (de) Verfahren zur behandlung von krebs
EP4017489A4 (de) Verfahren zur behandlung von kras-assoziertem krebs
EP3937964A4 (de) Behandlung von onkogengesteuerten krebsarten
EP3886867A4 (de) Verfahren zur behandlung von whsc1-überexprimierendem krebs durch hemmung von setd2
EP4028044A4 (de) Verfahren zur behandlung von kras-mutantem krebs
EP3976833A4 (de) Verfahren zur behandlung von krebserkrankungen der harnwege
EP4125879A4 (de) Verfahren zur behandlung von mit proteinopathie assoziiertem wandern
EP3775171A4 (de) Verfahren zur behandlung von minimalem restkrebs
EP3787625A4 (de) Verfahren zur behandlung von krebs
EP3908650A4 (de) Verfahren zur behandlung von krebs
EP4161495A4 (de) Personalisierte verfahren zur behandlung von krebs
EP4181925A4 (de) Verfahren zur behandlung von proteinopathien
EP3952858A4 (de) Verfahren zur tumorbehandlung
EP3781215A4 (de) Verfahren zur behandlung von krebs
EP4103286A4 (de) Verfahren zur behandlung von bauchspeicheldrüsenkrebs
EP3946419A4 (de) Verfahren zur behandlung von krebs mit chk1-inhibitoren
EP3852816A4 (de) Verfahren zur behandlung von krebs
EP4072561A4 (de) Verfahren zur behandlung von krebs
EP4111202A4 (de) Verfahren zur behandlung von krebs
AU2021372815A9 (en) Combination treatment of cancer
EP3993875A4 (de) Verfahren zur behandlung von braf-mutierten krebszellen
AU2023901353A0 (en) Methods of treating ALT-dependent cancers
EP3969623A4 (de) Verfahren zur behandlung von krebs mit chk1-inhibitoren
EP3860655A4 (de) Verfahren zur behandlung von flt3-mutiertem blutkrebs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090925

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/04 20060101ALI20240202BHEP

Ipc: A61P 1/04 20060101ALI20240202BHEP

Ipc: A61K 51/00 20060101ALI20240202BHEP

Ipc: A61K 49/04 20060101ALI20240202BHEP

Ipc: A61K 39/395 20060101ALI20240202BHEP

Ipc: A61K 31/4745 20060101AFI20240202BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20240430

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/04 20060101ALI20240424BHEP

Ipc: A61P 1/04 20060101ALI20240424BHEP

Ipc: A61K 51/00 20060101ALI20240424BHEP

Ipc: A61K 49/04 20060101ALI20240424BHEP

Ipc: A61K 39/395 20060101ALI20240424BHEP

Ipc: A61K 31/4745 20060101AFI20240424BHEP